highly significantP<0.001
The FT-AT AUROCs predictive values for survival without HBV complications were still highly significant after exclusion of 16 patients with FT high-risk profiles of false positives/negatives (n = 1,058 AUROC = 0.88, 95%CI 0.81–0.92; P<0.001), Impact of HBV treatment on biomarkers Among the treated patients, the first FT has been performed in 276 patients before treatment and among 370 patients during or after treatment.